Vosselaar, Belgium

Eleonora Jovcheva



 

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Eleonora Jovcheva: Innovator in Cancer Treatment

Introduction

Eleonora Jovcheva is a prominent inventor based in Vosselaar, Belgium. She has made significant contributions to the field of cancer treatment through her innovative research and development of pharmaceutical compositions. With a total of four patents to her name, her work focuses on combining various inhibitors to enhance therapeutic efficacy.

Latest Patents

Jovcheva's latest patents include a combination of an FGFR inhibitor and a cMet inhibitor. This invention relates to a specific combination of compounds aimed at treating proliferative disorders, particularly cancer. The FGFR inhibitor and the cMet inhibitor can be administered simultaneously, separately, or sequentially, providing flexibility in treatment options. Additionally, she has developed a combination of an FGFR inhibitor and an IGF1R inhibitor, which also targets cancer treatment. This combination can similarly be administered in various ways, and it includes a pharmaceutical composition with a suitable carrier.

Career Highlights

Eleonora Jovcheva is currently associated with Astex Therapeutics Limited, where she continues to advance her research in oncology. Her work is characterized by a commitment to improving patient outcomes through innovative drug combinations.

Collaborations

Jovcheva collaborates with Timothy Pietro Suren Perera, contributing to the development of groundbreaking treatments in the pharmaceutical industry.

Conclusion

Eleonora Jovcheva's contributions to cancer treatment through her innovative patents and collaborations highlight her role as a leading inventor in the pharmaceutical field. Her work continues to pave the way for new therapeutic strategies in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…